• PlantX to display and sell its indoor plants at Farm Cup Coffee’s highly attractive West Hollywood location
• The careful partnership aligns perfectly with PlantX’s commitment to supporting healthy lifestyles and community empowerment
• PlantX opens wide the potential of indoor plants, making it both easy and appealing to discover what the world of plants can provide

As the digital face of the plant-based community, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is taking another step to solidify its position as a one-stop shop for everything plant-based. The Company recently announced that has entered into a new collaboration with Farm Cup Coffee, an innovative coffee shop that offers organic coffee that is ethically sourced from farm owners around the world. PlantX will display and sell its houseplants at Farm Cup Coffee’s new physical location in West Hollywood, California (https://ibn.fm/TADOE).

“Displaying our indoor plants in the highly attractive Farm Cup Coffee store in West Hollywood will expand PlantX’s reach to its customers and boost our brand visibility,” said PlantX founder Sean Dollinger. “We are thrilled to collaborate with the Farm Cup Coffee team, whose passion for sustainability is echoed by PlantX’s aim to inspire people to adopt healthier, more eco-friendly lifestyles.”

PlantX anticipated that the collaboration will heighten its presence in one of L.A.’s most sought-after retail locations. The company will be displaying a wide range of indoor plants, from succulents to an exotic variety of potted flora. The carefully thought-out partnership aligns perfectly with PlantX’s commitment to supporting healthy lifestyles and community empowerment.

Indoor plants are only a fresh and beautiful introduction to what PlantX offers. The Company’s mission is to raise plant awareness in a hyper-palatable world to simplify plant-based living. PlantX lives its mission by striving to deliver the highest-quality products with the best service available.

And the PlantX product offering is widespread. From its line of indoor plants, which are now on display at Farm Cup Coffee, to its groceries, meal deliveries and plant-based gifts, the Company opens wide the potential of plants, making it both easy and appealing to discover what the world of plants can provide.

Partnering with Farm Cup Coffee in this endeavor was a no-brainer. The brand, which began in a Citroen van outfitted as a mobile and stylish coffee shop, focuses on positivity and is committed to sustainability. “We not only want you to drink good coffee, we want you to feel good drinking it too,” said Farm Cup Coffee co-founder Tony Yuan. “This harmonious partnership with PlantX at our West Hollywood location will help promote a happy and sustainable lifestyle for the local community.

With its fast-growing category verticals, PlantX offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans to expand its product lines to include cosmetics, clothing and its own water brand. PlantX uses its digital platform to build a community of like-minded consumers and, most importantly, provide education.

To learn more about this company, visit www.PlantX.com, www.PlantX.ca and www.Investor.Plantx.com and view the PlantX for Plant-Based Investors.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• POAI subsidiary inks contract with significant pharmaceutical company
• TumorGenesis announces sale of media to research medical centers in New York City, Boston
• Potential market for 3D cancer cell culture media expected to reach $3.2 billion sales worldwide by 2027

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that one of its wholly owned subsidiaries, Soluble Biotech, recently inked another contract with a large pharmaceutical company (https://ibn.fm/OpaJb). POAI also announced that TumorGenesis, one of its wholly owned subsidiaries, has sold media to two top research medical centers (https://ibn.fm/uXorQ).

Soluble Biotech’s contract will involve using the company’s proprietary protein formulation technology to improve the solubility and stability of a protein therapeutic destined for future clinical use.

“This opportunity may also lead to a long-term relationship whereby Soluble Biotech develops a strategic partnership to support several other therapeutics currently under development within the pharmaceutical company,” said Soluble Biotech Founder and President Dr. Larry DeLucas.

In additional company news, Predictive Oncology shared details about the sale of media to two top research medical centers. The sales by TumorGenesis, POAI’s wholly owned subsidiary, were repeat orders from hospitals in New York City and Boston, and included culturing ovarian cancer cells with specific research goals.

“We believe that this is the future of ovarian cancer research, which creates new possibilities to coming up with new treatments for this chronic and deadly disease,” said Predictive Oncology President and CEO Dr. Carl Schwartz. “In order for us to find better drugs, we have to be able to grow the right patient cells in the right media. Building the ‘living library’ of cancer cells for drug screening and discovery is the right first step.” POAI is committed to this first step and is the process of building the largest existing database of drug response data in the world.

The announcement noted that TumorGenesis can replicate ovarian cancer cells in a laboratory—outside of the patient’s body. The company has 15 ovarian cancer cell lines along with the media to grow those cells.

“These tissues, in the right TumorGenesis media, replicate not only the DNA/RNA and proteomic signatures but also replicate the histological structures that can be seen in staining, outside the patient’s body,” said TumorGenesis President and board member Richard Gabriel. The process produces invaluable information that can be used by oncologists and other cancer treatment experts to potentially identify and prescribe treatments and care for cancer patients, resulting in more positive outcomes.

The potential market for what POAI does — 3D cancer cell culture media — is expected to reach $3.2 billion sales worldwide by 2027. The space is so explosive because it currently offers the best available models for cancer drug discovery and development.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Gage Cannabis recently closed on Regulation A equity financing offering, raising gross proceeds of $50 million
• Issuance was oversubscribed, resulted in addition of over 1,000 new investors to Gage Cannabis’ shareholder base
• Gage Cannabis plans to use the proceeds to further expand Gage’s retail reach, pursue M&A opportunities and help solidify the company’s position as one of the leading operators in the state of Michigan
• Company also announced appointment of Richard Mavrinac to Board of Directors

Gage Growth Corp. (d.b.a. Gage Cannabis) (“Gage Cannabis”), a leading vertically integrated cannabis operator currently focused exclusively on the Michigan market, recently announced that it had successfully concluded its Regulation A, Tier 2, equity financing offering. The equity issuance consisted of Gage Cannabis issuing 28,571,400 subordinate voting shares for total gross proceeds of $50 million, the maximum amount qualified under the company’s offering circular. The offering was oversubscribed by both institutional and retail investors and has led to a significant expansion of the company’s shareholder base through the addition of over 1,000 new investors (https://ibn.fm/gPEro). “We are humbled and excited by the significant interest and investor demand we received for our oversubscribed Reg A financing,” said Gage Cannabis President Fabian Monaco. “Michigan is one of the fastest growing cannabis markets in the United States, and Gage is well positioned with a robust balance sheet to continue to grow our market share as the leading operator with the best brands in the state. This is a great first step in our journey to becoming a publicly traded company, and we’re excited to continue to drive long-term shareholder value.” Gage Cannabis has been one of the prime beneficiaries from Michigan’s move to legalize the use of recreational marijuana in December 2019. Since then, Gage Cannabis has pursued an aggressive expansion plan, which has seen the company open 6 medical or adult-use locations across the state, with a further 10+ locations slated to open in 2021. The company’s rapidly expanding footprint has been largely predicated on the strong underlying sales growth witnessed within the sector. Cannabis retailers sold approximately $450 million worth of recreational marijuana products in the state of Michigan over the twelve months following the legalization decision on December 1, 2019, an achievement which was significantly boosted by the Michigan State Government’s decision to nominate the cannabis industry as an ‘essential sector’ during the COVID-19 outbreak (https://ibn.fm/YsVHi). Remarkably, the sector’s sales have continued to thrive, rising to a run-rate of over $13 million a week in recent months (https://ibn.fm/umNmb). Should that rate be maintained, sales growth for the sector could rise by nearly 400 percent year-over-year to approximately $1.6 billion over the course of the next year. “It really is just explosive growth in Michigan,” stated Sloane Barbour, the chief revenue officer of cannabis industry recruitment agency FlowerHire (https://ibn.fm/nBNua). Gage Cannabis plans to use the proceeds from its recently closed Regulation A equity financing to further cement a dominant position within the Michigan state marijuana industry by expanding its retail footprint and pursuing accretive acquisitions which could assist in further expanding their market share. The company has also stated its intent to pursue a potential go-public transaction, which it expects to complete in the first quarter of 2021. In addition to the equity issuance, Gage Cannabis also seized on the opportunity to update investors on a recent addition to the company’s Board of Directors. Richard Mavrinac, formerly the CFO of George Weston Limited and Executive Vice President of Loblaw Companies Limited, two of Canada’s largest companies operating in the retail grocery and bakery sectors, will be joining Gage Cannabis’ board to assist the company on its future growth strategy. Mr. Mavrinac is also a member of the Board of Directors of TerrAscend Corp., Roots Corporation and Canopy Rivers Inc., and will bring a significant wealth of experience within the retail and cannabis sector to Gage Cannabis executive team. For more information, visit the company’s website at www.GageUSA.com. NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://ibn.fm/GAGE

• Founders Robert A. Rositano Jr. and Dean Rositano have over 25 years of experience that includes the first-ever Internet IPO and World Wide Web Directory
• The Rositano brothers released a disruptive social network, nettaxi.com, before Facebook became popular, exiting the industry with approximately a $700 million market cap
• Fan Pass recently appointed media and digital advertising expert John Haugh as the VP of sales, operations, and business development
• Friendable Inc. plans to continue expanding and innovating the Fan Pass platform, addressing all artist needs and desires through their platform and Pro Serives

Since being founded by entrepreneurial brothers Robert A. Rositano Jr. and Dean Rositano, mobile technology and marketing company Friendable (OTC: FDBL) has leveraged their expertise and over 25 years of experience in tech-related startups, to release flagship product Friendable, followed by a second application, Fan Pass, to great success. With an impressive background in team building and turning ideas into big business opportunities, the Rositano brothers have raised over $65+ million in capital that spans various companies. Their history dates back to the first-ever Internet IPO, Netcom Online Communications. They are also responsible for developing the first-ever World Wide Web Directory, which was sold to McMillan Publishing. Before Facebook, they deployed the first mover social network, nettaxi.com, which exited with a market cap of approximately $700 million. The two have leveraged their extensive experience to create Friendable’s first product, Friendable, a social application that facilitates one-on-one and group-style meets that create non-threatening and all-inclusive meeting settings. The focus of the application is to build subscription-based revenue where “everything starts with friendship.” This was followed by the company’s second application, Fan Pass, launched in July 2020. In the middle of a global pandemic, Friendable released a subscription service that provides fans with an “All Access VIP” option, including:

• Live performances and online concerts
• Backstage access to artists for meetups – before, during, and after events
• Livestreams of in-studio sessions
• Behind-the-scenes footage of video and photoshoots
• Special interviews with one-on-one video experiences
• Streams that highlight the daily lives of the artist

Fan Pass’s intuitive platform brings each artist on, providing them with a streamlined channel, livestream space, and merchandise that can be offered exclusively through the Fan Pass merchandise store. Knowing that artists rely on their revenue streams, each artist who comes on board receives a portion of the revenue from the subscriptions and pay-per-view events. Fans pay a monthly fee of $3.99 for daily access to the artists on the platform. The VIP experiences are available at a fraction of the cost of traditional face-to-face encounters. Pay-per-view concert events are livestreamed straight to your smart device, cheaper than in-person concert tickets. While kicking off the February 2021 promotional period earlier this month, Friendable announced the addition of John Haugh to the Fan Pass team (https://ibn.fm/oM4UZ). Mr. Haugh joined the team as the VP of sales, operations, and business development. He has over 25 years of experience and over 10,000 touring miles to bring to the team, having been a musical performance artist. He has had regular correspondence with familiar industry names such as WEA, Sony Music, Universal, Atlantic, RED Distribution, Warner Brothers, Virgin Music, and more. Mr. Haugh also brings with him an extensive repertoire representing advertising agencies and marketing managers, securing advertising dollars and relationships with notable companies like Nissan and Intel. He has handled event partnerships and national media purchases with multi-million dollar budgets. These experiences provided him with a powerful vision for the shift to digital marketing. “We are blessed and excited to have Mr. Haugh join our team,” Friendable CEO Robert A. Rositano Jr. said about Haugh’s appointment. “He has firsthand knowledge of what it takes to be a touring music artist and, even more importantly, understands the pain points of artists and where Fan Pass can be the most supportive as we continue with our platform updates, new features, revenue opportunities, and overall growth plans for the Company.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• InsuraGuest renews InsuraGuest Hospitality Liability coverages contract with Wintergreen resort
• InsuraGuest recently expanded platform integration to about 82 different property management systems connecting with all the big names in the hospitality sector
• InsureThePeople is integrating innovation and technology to deliver to the U.S small business market

InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF)  is an insurtech (insurance+technology) company engaged in delivering digital insurance to multiple sectors through its proprietary software platform. The company harnesses the power of technology to deliver insurance digitally across all sectors, empowering clients by offering on-demand insurance products. Insuraguest Technologies recently announced the renewal of its annual contract with Wintergreen Resort in Wintergreen, Virginia, to supply its InsuraGuest Hospitality Liability coverages to the hotel Resort. This specialized guest protection policy is the first line of defense for both the property and the guest (https://ibn.fm/ob2jP). The hotels and rental properties who enroll in the InsuraGuest Hospitality Liability coverages. require their guests to pay a nominal fee at the time of check-in. InsuraGuest then pays out these small claims, shifting the burden from the hotel operator. With no surge in premium prices, there is no impact on the company’s liability policy. With InsuraGuest Hospitality Liability specialized coverages, properties benefit from an additional layer of protection in case a guest encounters an accident, room-damage, theft, or property damage. This prevents the need to make GL claims if an InsuraGuest-covered claim occurs and reduces the hassle, saving time and money for hotel and vacation rental properties. InsuraGuest utilizes a proprietary software platform to deliver these specialized Hospitality Liability coverages. Through its proprietary API, InsuraGuest syncs about 82 different property management systems that allow companies to transfer certain liability exposures to the InsuraGuest carrier (https://ibn.fm/evDmc). InsureThePeople helps small-businesses identify their insurance needs and provides them with on-demand affordable policies. It utilizes InsuraGuest’s proprietary insurtech platform to deliver these customized policies using automation and digital solutions in less than 60 seconds. InsureThePeople hopes to leverage the market of small businesses that make up 99% of America’s 28.7 million businesses. Further, the entrepreneur and freelance markets include 64.8 million people and will reach 90 million by 2028, with an estimated value of $1.8 billion. The last decade has witnessed an investment of $16.5 billion in insurtech, with the emergence of insurtech startups and a sharp increase in fundraising. Insurtech startups are entering the domain of the big players by focusing on meeting the changing consumer demands through increased personalization, greater speed, and accuracy of services through technology. A recent Forbes article (https://ibn.fm/jNL6t) outlines this technological innovation in the digital insurance sector. While InsuraGuest systems already target niche markets like the hospitality sector, the company is geared to extend its services to broader audiences to generate additional revenue streams. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• With Mediscan, the option of having scanning equipment at patient’s location is becoming increasingly viable
• Patent-pending Mediscan software converts ultrasound analog 2D grayscale image into digital 3D HD format
• Software can generate quality 3D medical images of broad variety of organs, including heart, lungs, tendons, skin and nerves

Since its introduction into the world of medicine, the ultrasound has become one of the most efficient, reliable ways to examine the human body in a noninvasive way. And now, this medical mainstay has become even more essential in providing quality care — proprietary technology from HYB Holding (OTC: HYBG) subsidiary Mediscan Inc. can transform traditional 2D images from a portable ultrasound machine into invaluable 3D images to provide even more accurate internal views and, consequently, better diagnosis and health care. “Ultrasounds give an accurate image of body parts in the least amount of time, and even allow the patient to experience real-time results,” reported a recent Mediscan blog. “In fact, [ultrasounds] can produce a high-definition image in less than ten seconds.” That turnaround time is impressive, especially when compared to technologies such as CTs and MRIs, which can take anywhere from 24 hours to an entire week before results are available. The speed of ultrasounds becomes even more critical during emergencies, when the ability to have point-of-care ultrasound (“POCUS”) can save lives. Thanks to Mediscan, the option of having scanning equipment at a patient’s location — whether that is in an ambulance, at an assisted-living facility or even at a patient’s own home — is becoming increasingly viable. Fundamentally, the Mediscan software converts an ultrasound analog 2D grayscale image into a digital 3D HD format. This transformation can take place in traditional ultrasound locations; the Mediscan application integrates with all popular EMR systems. In addition, because the software is designed to pair with portable ultrasound machines, it can be used in less traditional settings. The exclusive software can provide valuable insight to on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (EMS) personnel, and technicians in isolation wards and emergency rooms. The process is simple. This patent-pending, cloud-based software application for ultrasound devices is easy to use wherever the internet is available. Once an image has been captured in 2D, it is converted using a cloud-based software application process. The now-3D image can be viewed on a computer monitor, pad or smartphone at the point of service, providing the convenience of point-of-care ultrasound with the image quality of CT or X-ray and the safety of expensive MRI technology. The software can generate quality 3D medical images of a broad variety of organs, including the heart, lungs, tendons, skin and nerves. HYB Holding, through its subsidiary Mediscan Inc., offers technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology has multiple applications in lung, cardiac and musculoskeletal imaging and related uses. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HYBG are available in the company’s newsroom at https://ibn.fm/HYBG

• Knightscope, Inc. designs, engineers, builds, deploys, and services autonomous data machines (“ADMs”) also known as security robots
• It currently offers three operational robots in the U.S.: K1 Stationary, K3 Indoors, and K5 Outdoors
• The robots are cheaper for clients per hour compared to human guards and run 24/7
• Knightscope charges between $4 and $11 per hour for its machines on annual contracts, while security companies can charge between $15 and $35 an hour for an unarmed guard and about $85 per hour for an armed guard, according to Knightscope’s CEO
• Investors can purchase shares in Knightscope through its Reg A+ offering
• Since its inception in 2013, Knightscope has generated over $10 million in revenue

Knightscope, a private company that designs, engineers, builds, deploys, and services security robots under the Machine-as-a-Service (“MaaS”) model, aims to woo clients and investors with its cost-effective autonomous data machines (“ADMs”). The California-based company, which was established in 2013, has so far raised $70 million from over 20,000 investors and four major corporations. It is eyeing a possible public listing on NASDAQ under the ticker symbol ‘KSCP’. Knightscope currently offers three operational autonomous machines, namely K1, K3, and K5. K1 is a stationary ADM ideal for indoor and outdoor use at ingress and egress areas, while the latter two are mobile. K3 is designed for indoor usage, while K5 is an outdoor-only ADM. According to its Securities and Exchange Commission (“SEC”) filings, Knightscope earns a revenue ranging between $4,500 and $6,000 per month per ADM. It has so far generated over $10 million in revenue since its inception in 2013 from clients who include hospitals, Fortune 1000 companies, and law enforcement agencies (https://ibn.fm/n7x0i). In a bid to drum up support for its Reg A+ offering, which allows investors to purchase shares in Knightscope today, and to show why clients would be interested in the security robots, William Santana Li, Knightscope’s Chairman and Chief Executive Officer, compared his company’s products to human security guards. According to Li, clients would pay about $85 per hour for an armed guard and between $15 and $35 an hour for an unarmed guard if they chose to go that route. However, in an interview with IPO Edge, Li claimed that his company offers “a technology and a Machine-as-a-Service business model at an effective price of $4 to $11 an hour.” “Most security teams look like a cost center for their clients. They don’t generate revenue, (are) not necessarily brand-enhancing, are usually on the chopping block, and (get) limited budget and resources until something goes wrong. Then they get accused of not doing their job.” Li continued. He termed such a situation as difficult for an organization. He further noted that his company is an attractive option for clients, given that “Folks are either limited on budget or looking genuinely for cost reduction. So, if you’re burning $150 million a year on security guards, you’re going to want to look at it (Knightscope’s services and products)” (https://ibn.fm/QsV10). Li also debunked the conjecture that $4 and $11 an hour would be too low an amount to compel someone to invest in Knightscope. “We sign year-long contracts running 24/7. So, each machine will generate on the order of $70,000 and $100,000 per annum. It costs us less than $60,000 to build the machine. So, the idea is to recover the cost of the machine in the first calendar years, and then the second, third, fourth, fifth year you are basically printing money.” Taking maintenance and service costs, cellular charges, and system upgrade costs into account, Santana estimates that each machine could generate up to $250,000 in profit over five years. The ADMs have numerous capabilities. They provide real-time access to data round the clock. For example, in a year, the machines generate over 90 terabytes of data that can be used for analysis purposes. And that’s not all. They also have features such as 360-degree eye-level HD video streaming, thermal anomaly detection, automatic license plate recognition (at a rate of 1,200 plates per minute), people detection, facial recognition (even for people wearing masks), and automatic signal detection. While the CEO’s utterances show promise and demonstrate Knightscope’s ideal prospects, the SEC filings tell a different story. Knightscope has been operating in the red. In the six months ending June 2019 and June 2020, the company reported net losses of $6.99 million and $9.14 million, respectively. Further, in the six months that followed, Knightscope posted $11.96 million and $13.39 million in net losses for the period ending December 2019 and December 2020, respectively. Knightscope CEO stated that the Company has built all of its technology from scratch and is now raising capital to scale the business to profitability. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Life sciences industry accelerator XPhyto Therapeutics Corp. has developed a timeline for the approval and rollout of a rapid, portable COVID-19 test it expects to become available by April in Europe
• XPhyto’s Covid-ID Lab system is designed to help industries economically devastated by the pandemic to form strategies based on quick and accurate testing, particularly the travel industry
• The company intends to use its test tech partnership with Germany’s 3a-diagnostics GmbH to build additional bacteriological and viral testing products
• A separate subsidiary based in Alberta is developing psychedelic medicine programs
• The subsidiary recently announced it has added mescaline production to the program for potential use in treating addiction and depression

Canada-based bioscience accelerator XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has completed all the preparatory actions necessary for it to apply for approval of its COVID-19 rapid and portable test system under European regulatory authorities, the company announced Feb. 16. The quick-response point-of-care SARS-CoV-2 RT-PCR Test System known as “Covid-ID Lab” developed in partnership with Germany’s 3a-diagnostics GmbH is designed to provide robust and accurate COVID-19 testing for economically devastated market sectors, with particular emphasis on travel industries. The announcement is one of a pair of company developments to emerge this month, including the expansion of the holding company’s psychedelic medicine programs. In regard to the COVID test, 3a expects to obtain approval as a medical device manufacturer under internationally agreed-on ISO 13485 quality standards by late February, followed by European regulatory approval of Covid-ID Lab as a commercial in vitro diagnostic device (CE-IVD) by early March, according to the company’s announcement (https://ibn.fm/89jKh). The companies then plan for manufacturing to begin in Germany with an April target for Covid-ID Lab’s sales launch in Europe. XPhyto is building relationships with partners in other countries to further advance the system’s sales and distribution. “Our goal was to create the fastest and most portable COVID-19 PCR test on the market,” XPhyto CEO and Director Hugh Rogers stated. “We are very pleased with the team’s swift development progress.” The pandemic has had a calamitous effect on the tourism industry during the past year, especially for popular island destinations ranging from Hawaii to Australia and New Zealand. Domestically, Hawaii has experimented with resort “bubbles” and recently announced a test-dependent Health Pass agreement that will help travelers avoid a mandatory 10-day quarantine once they arrive on the islands (https://ibn.fm/yuQQd), while United Airlines became the first U.S. carrier to establish an in-airport testing partner and information service, according to a CBS News report (https://ibn.fm/Af5A6). But the growing spread of COVID virus variants from the United Kingdom, South Africa and Brazil is creating new urgency about safeguarding international travel. India’s new air travel guidelines issued Feb. 18 are just the latest efforts to limit transmission of the worldwide health crisis, and experts believe varied restrictions will remain in place for a long time to come. “Like 9/11 changed air security forever, we’re still taking our shoes off,” XpresCheck CEO Doug Satzman stated in the CBS News report. “COVID is going to change safety protocol in airports for a long time as well.” The U.S. Centers for Disease Control and Prevention (“CDC”) has advised against such travel entirely, but has added testing recommendations for people who ignore its advice. In late January, the agency broadened international travel requirements, making negative COVID tests mandatory for passengers coming from any international location to the United States despite airline industry resistance (https://ibn.fm/rnoG3). XPhyto’s rapid-response test system aims to give businesses and government authorities a powerful tool in their arsenals, and the COVID response is only the beginning. The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, and is focusing on other potential pandemic biosensor tech efforts to combat the spread of the H1N1 (swine flu) and H5N1 (avian flu) viruses. The company states it is planning to launch its first biosensor product commercially during the latter half of 2021. Elsewhere, one of XPhyto’s holdings in Canada, XPhyto Laboratories Inc., has added mescaline production to its psychedelic medicine programs, according to a Feb. 3 announcement (https://ibn.fm/zyiEL). Mescaline is listed as a Schedule I drug in the United States without legally recognized medicinal benefits and with a high risk of abuse, but the psychedelic substance occurs naturally in some types of cactus and has limited legal use in certain religious ceremonies registered by the Native American Church and in certain research efforts. However, its use is expanding internationally as a supplement to various types of meditation and psychedelic therapies, according to the company. “Mescaline has been anecdotally recognized as a relatively safe psychedelic drug and has shown particular promise for the treatment of addiction and depression,” XPhyto’s news release states. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• PULL recently received Company Code from Canada’s Natural and Non-prescription Health Products Directorate
• Code allows PULL to submit application to sell its first functional mushroom product
• Company intends to submit additional NPN applications during 2021 as part of larger strategy to develop portfolio of functional mushroom wellness products

Functional mushrooms, those that provide a health benefit beyond just nutrition, are growing in popularity worldwide amid an accelerating trend to fend off viruses with immune-boosting food and drinks. Looking to seize part of a global functional mushroom market forecast by Data Bridge Market Research to hit $555.9 billion by 2028, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is checking the boxes to soon commercialize its new line of products.

Pure Extracts, a diversified plant-based extraction company with reach into cannabis, hemp, functional mushrooms and the burgeoning psychedelics sector, recently received a Company Code from Canada’s Natural and Non-prescription Health Products Directorate (“NNHPD”), an important step in moving towards sales. The code allowed the Company to submit an application for a Class 1 Natural Product Number, or NPN for short, for its first functional mushroom product.

Products that receive an 8-digit NPN have been assessed by Health Canada and deemed to be safe, effective and of high quality under the recommended conditions of use. Once approved, the NPN is added to the Licensed Natural Health Products Database where information about the product is available for viewing. The database includes information on a variety of natural health products, such as vitamin supplements, herb and plant-based remedies, probiotics, traditional medicines and more.

Pure Extracts intends to submit additional NPN applications during 2021 as part of its strategy to develop a portfolio of functional mushroom wellness products to sell through Pure Mushrooms Corp., its new, 100%-owned, subsidiary. Pure Mushrooms will employ a direct-to-consumer model, selling its goods through an e-Commerce portal being designed while the licensing process is under way. The new products will be sold under the “Pure Mushrooms” moniker.

Initially, the Company will work with a co-packer to meet consumer demand for Pure Mushrooms products while it explores optimizing existing extraction equipment at its state-of-the-art processing facility outside of Whistler, British Columbia. Planning ahead, Pure Extracts, which holds a Standard Processing License from Health Canada allowing it to manufacture cannabis goods, had its purpose-built facility constructed to meet Good Manufacturing Practices standards of the European Union, aligning for future global distribution of products and formulations were allowed by law.

Pure Extracts CEO Ben Nikolaevsky commented that his team is excited about the milestones ahead to enter the functional mushroom wellness sector that is experiencing “tremendous growth and consumer awareness.” He added that the company expects sales of the new products to begin by the end of this quarter.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Imagin Medical Inc. announced that it has now raised $2.165 million of the recent its convertible note offering
• The closing of the latest funding tranche will support the company’s progress toward the commercialization of its revolutionary bladder cancer visualization technology once final FDA approval is granted
• With better viewing options, the technology is designed to make it easier for surgeons to detect the full parameters of bladder tumors and remove them more completely
• Bladder cancer is one of the most prevalent cancers in the United States, particularly in men
• The technological improvement of these surgical procedures can provide an attractive cost benefit outcome and improved peace of mind as the potential need for repeated tumor-resecting procedures is reduced

As Imagin Medical (CSE: IME) (OTCQB: IMEXF) announces the closing of the second tranche of a convertible note offering to investors, the company continues building momentum toward the anticipated commercialization of its revolutionary cancer visualization technology. Imagin’s proprietary i/Blue Imaging (TM) System is a means of improving cystoscopies through the simultaneous use of white and blue imaging protocols that allow surgeons to detect and resect bladder tumors with greater accuracy and ease than has been possible before. The second tranche closing, announced Feb. 18 (https://ibn.fm/8gVHc), brings the amount raised for Imagin’s convertible note up to $2.165 million. Principal of notes that will accrue 10 percent interest annually and mature 18 months after the date of issue unless they are repurchased, redeemed or converted before that time. Imagin is aiming to commercialize its i/Blue Imaging (TM) System once final U.S. Food and Drug Administration (“FDA”) approval has been granted, and then apply its experience with the system toward the manufacture and commercialization of similar technology for use in other types of surgical procedures, i.e. laparoscopic. The I/Blue System uses blue light with a contrast agent, Cysview(TM) that causes the tumor to fluoresce  agent and deliver real-time images of the bladder for resection. While the existing blue light system has required surgeons to switch back and forth between white and blue light images, Imagin’s IP simplifies the process and makes it more effective by showing the white and blue light images side-by-side on the same monitor, utilizing hardware that is compatible with almost any endoscope already in use by hospitals and surgical centers so that they don’t have to acquire entirely new systems. The company estimates that approximately 95 percent of today’s cystoscopies continue to be performed with white light simply because of the hardware costs and challenges of acquiring blue light capability. Photocure reported to the 21st Annual Meeting of the Society of Urologic Oncology in December that its latest investigation found Cysview didn’t significantly affect the cost of cystoscopies and helped surgeons find tumor recurrences that would otherwise have been missed (https://ibn.fm/t9SLP). A report by Urology Times found that the use of blue light cystoscopy (“BLC”) under the trade name Cysview in tandem with white light during initial transurethral resection of bladder tumors (“TURB”) “lowered costs by $4,660 over 5 years compared with use of white light cystoscopy alone” and led to a lower overall burden for patients (https://ibn.fm/Cz8GX). For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF